Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer

Area of Science:

• Oncology
• Pharmacology
• Drug Resistance

Background:

• Ixabepilone, an epothilone B analog, exhibits low susceptibility to drug resistance mechanisms.
• It has demonstrated clinical efficacy in patients with metastatic breast cancer (MBC) refractory to other chemotherapies.
• The FDA-approved dose is 40 mg/m(2) every 3 weeks, often combined with capecitabine or as monotherapy after capecitabine failure.

Purpose of the Study:

• To evaluate alternative dosing schedules for ixabepilone to improve its risk/benefit profile.
• To compare the tolerability of weekly versus every-3-week ixabepilone administration in MBC patients.

Main Methods:

• A Phase II trial compared weekly ixabepilone (16 mg/m(2) on Days 1, 8, 15 of 28-day cycle) versus every 3 weeks (40 mg/m(2) on Day 1 of 21-day cycle).
• Adverse events (AEs), particularly myelosuppression and peripheral neuropathy, were monitored.
• Hematologic, neurologic, and liver function were assessed for dose modification guidance.

Main Results:

• Both weekly and every-3-week schedules demonstrated useful efficacy and reasonable tolerability.
• Preliminary data indicated that the weekly schedule may have a more favorable safety profile with fewer AEs compared to the every-3-week schedule.
• Common dose-limiting toxicities include myelosuppression and peripheral neuropathy, manageable with dose modifications.

Conclusions:

• Ixabepilone is an effective treatment option for patients with MBC resistant to taxanes and anthracyclines.
• Alternative dosing schedules, such as weekly administration, warrant further investigation to optimize ixabepilone's tolerability and therapeutic index.
• Ongoing research is exploring ixabepilone in combination therapies and earlier breast cancer settings.